74900-81-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(Allyloxy)aniline is used as a reagent for the preparation of Bz-?aminoindoles and Bz-?methoxyindoles, which are important intermediates in the synthesis of various pharmaceutical compounds. These indole derivatives have potential applications in the development of drugs targeting specific biological pathways and receptors.
Used in Organic Synthesis:
3-(Allyloxy)aniline is used as a key building block in the synthesis of a wide range of organic compounds, including natural products, pharmaceuticals, and agrochemicals. Its reactivity and functional groups allow for various chemical transformations, making it a valuable component in the development of new molecules with desired properties.
Used in Chemical Research:
3-(Allyloxy)aniline serves as a model compound in chemical research, particularly in the study of reaction mechanisms, catalysts, and new synthetic methodologies. Its unique structure and reactivity provide insights into the fundamental aspects of organic chemistry and contribute to the advancement of the field.

InChI:InChI=1/C9H11NO/c1-2-6-11-9-5-3-4-8(10)7-9/h2-5,7H,1,6,10H2

Upstream product

• 898161-44-9 tert-butyl (3-(allyloxy)phenyl)carbamate 
• 19962-06-2 tert-butyl 3-hydroxyphenylcarbamate 
• 37439-78-4 N-(3-(allyloxy)phenyl)acetamide 
• 621-42-1 meta-hydroxyacetanilide 
• 554-84-7 meta-nitrophenol 
• 58621-55-9 1-allyloxy-3-nitro-benzene 

Downstream Products

• 1443438-12-7 C₂₄H₂₂F₆N₂O₃ 
• 102879-28-7 m-allyloxyaniline hydrochloride 
• 1214923-70-2 N₄-(3-allyloxy-cyclohexyl)-N₂-(3-allyloxy-phenyl)-5-fluoro-pyrimidine-2,4-diamine 
• 1346652-11-6 N₂-(4-(allyloxy)benzyl)-N₄-(3-(allyloxy)phenyl)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine-2,4-diamine trifluoroacetate 
• 1346652-14-9 N₂,N₄-bis(3-(allyloxy)phenyl)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine-2,4-diamine trifluoroacetate 
• 1346652-09-2 4-((4-(3-(allyloxy)phenylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)-methyl)phenol trifluoroacetate 
• 1214923-74-6 N₄-(4-(allyloxy)cyclohexyl)-N₂-(3-(allyloxy)phenyl)-5-fluoropyrimidine-2,4-diamine 
• 937273-28-4 (3-allyloxyphenyl)-[4-(3-but-3-enyloxyphenyl)pyrimidin-2-yl]amine 
• 116924-94-8 S-Ethyl 3-allyloxy thiolcarbanilate 
• 892413-66-0 2,4-bis[[3-(2-propenyloxy)phenyl]amino]-5-pyrimidinecarbonitrile 
• 112049-11-3 4-methyl-piperazine-1-carbothioic acid-(3-allyloxy-anilide) 
• 875244-00-1 3-allyloxy-phenyl isothiocyanate 

Relevant academic research and scientific papers

BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Silver-Mediated Trifluoromethoxylation of (Hetero)aryldiazonium Tetrafluoroborates

Here we report a silver-mediated trifluoromethoxylation of (hetero)aryldiazonium tetrafluoroborates by converting an aromatic amino group into an OCF3 group. This method, which can be considered to be a trifluoromethoxylation variation of the classic Sandmeyer-type reaction, uses readily available aryl and heteroaromatic amines as starting materials and AgOCF3 as trifluoromethoxylating reagents. The broad substrate scope and simple, mild reaction condition made this transformation a valuable method in constructing aryl-OCF3 bonds.

Self-Assembled Magnetic Gold Catalysts from Dual-Functional Boron Clusters

A new class of core–shell magnetic gold nanocomposites is prepared in a raspberry-like fashion by the controlled supramolecular host–guest assembly of γ-cyclodextrins (γ-CDs) and boron clusters. In this work, Cs2[closo-B12H12], a fundamental boron cluster, can play a dual role in the preparation of highly monodispersed Au nanoparticles and in the immobilization of Au nanoparticles on the γ-CDs@Fe3O4 surface as an effective anchor. This facile and spontaneous supramolecular strategy allows for the control of the size and composition of the highly stable gold composites. Furthermore, the obtained AuNPs@Fe3O4 composites exhibit an excellent catalytic activity and recyclability for the selective reduction of nitroaromatics to their corresponding aniline compounds, and the fastest reaction can be achieved within 20 s with a high conversion and selectivity at room temperature, which is better than that obtained previously in studies on metal nanoparticle composites as catalysts.

MACROCYCLIC KINASE INHIBITORS AND USES THEREOF

The present disclosure provides macrocyclic compounds of Formula (I). The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or pr

USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS

The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inh

In situ production of silver nanoparticles on an aldehyde-equipped conjugated porous polymer and subsequent heterogeneous reduction of aromatic nitro groups at room temperature

In a metal-free procedure, chelating thiol groups and an electrophile react to assemble a robust, conjugated porous polymer with pendant aldehyde functionalities. These groups are able to reduce Ag(I) ions to generate, in situ, Ag(0) nanoparticles evenly dispersed in the polymer matrix. The Ag(0)-polymer composite enables selective reduction of aromatic nitro compounds as a heterogeneous catalyst, and can be conveniently recycled multiple times.

Synthesis and anti-proliferative activity of substituted- anilinoquinazolines and its relation to EGFR inhibition

4-Anilinoquinazoline is a privileged scaffold in developing small molecule inhibitors of tyrosine kinases (TK) especially epidermal growth factor receptor (EGFR). 2 series belonging to 3'-substituted-4-anilinoquinazoline scaffold were synthesized and screened in vitro on isolated and a breast cancer cell line. The research aims at exploring the activity of compounds having diverse substituents at 3' position of the aniline moiety. Generally, the meta-substituted-anilinoquinazolines exhibited significant inhibitory activity against isolated enzyme as well as MCF-7 cancer cell line. For instance, compound 10b inhibited >99% of EGFR activities at 10 M concentration. 6 of the tested compounds exhibited range of anti-proliferative activity below 10 M potency. In particular, compounds 6e and 10b displayed the highest activity among the tested compounds with IC50 values equal to 8.6 and 4.84 M, respectively. Structure-based tools were utilized to rationalize EGFR-TK binding of compound 10b since it is the most active compound in the enzyme inhibition test. Georg Thieme Verlag KG Stuttgart.New York.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27) ,16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2 V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2 WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.

OXYGEN LINKED PYRIMIDINE DERIVATIVES

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.